Document:

Exhibit

Exhibit 10.16g

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 
[**] INDICATES THAT INFORMATION HAS BEEN REDACTED.
Execution Copy

AMENDMENT NO. 6 TO FOURTH AMENDED AND RESTATED 
RECEIVABLES PURCHASE AGREEMENT
THIS AMENDMENT NO. 6 to FOURTH AMENDED AND RESTATED RECEIVABLES PURCHASE AGREEMENT (this “Amendment”), dated as of June 25, 2020, is entered into among AUTOMOTIVE FINANCE CANADA INC.   an Ontario corporation (the “Seller” and the initial “Servicer”), KAR AUCTION SERVICES, INC., a Delaware corporation (the “Performance Guarantor”), and BNY TRUST COMPANY OF CANADA, in its capacity as trustee of PRECISION TRUST, an Ontario trust (the “Trust”).
R E C I T A L S
A.    The Seller, the Servicer, the Performance Guarantor and the Trust are parties to that certain Fourth Amended and Restated Receivables Purchase Agreement, dated as of December 20, 2016 (as amended, amended and restated, supplemented or otherwise modified prior to the date hereof, the “Agreement”).
B.    Pursuant to and in accordance with Section 10.4 of the Agreement, the Seller, the Servicer, the Performance Guarantor and the Trust desire to amend the Agreement as hereinafter set forth.
NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
1.Certain Defined Terms.  Capitalized terms which are used herein without definition and that are defined in the Agreement shall have the same meanings herein as in the Agreement.
2.    Amendments to Agreement.  The Agreement is hereby amended as follows:
2.1    Clause (c) of Section 2.5 of the Agreement (Allocation of Seller’s Share of  Collections Before the Termination Date) is amended as follows:
		
	(c)
	(i)  to the extent (A) the quotient of (I) the ‘NRPB’, plus the amount on deposit in the Cash Reserve Account, minus ‘I’, minus ‘DP” divided by (II) the ‘NRPB’ (as each such abbreviation is defined in the definition of “Trust’s Share”) would be less than [**]% if such funds were allocated to the Seller on account of the Seller’s Retained Interest or (B) the Trust has notified the Servicer in writing that allocations to the Seller on account of the Seller’s Retained Interest should cease, (x) to be retained in the Deposit Accounts or Collection Account until the following Business Day for allocation pursuant to Section 2.5 or 2.8, as applicable, on such following Business Day, or (y) to be allocated to repay the Investment pursuant to Section 2.13 or (ii) if the Trust has not notified the Servicer in writing that allocations to the Seller on account of the Seller’s Retained 

	
			
	 
	 
	 

Interest should cease, to be allocated to the Seller on account of the Seller’s Retained Interest but only to the extent that, after giving effect to such allocation, the quotient of (I) the ‘NRPB’, plus the amount on deposit in the Cash Reserve Account, minus ‘I’, minus ‘DP’ divided by (II) the ‘NRPB’ (as each such abbreviation is defined in the definition of “Trust’s Share”) is at least [**]%.
2.2    Clause (h) of Section 2.6 of the Agreement (Allocation of Trust’s Share of Collections Before the Termination Date) is amended as follows:
		
	(h)
	(i) to the extent (A) the quotient of (I) the ‘NRPB’, plus the amount on deposit in the Cash Reserve Account, minus ‘I’, minus ‘DP’ divided by (II) the ‘NRPB’ (as each such abbreviation is defined in the definition of “Trust’s Share”) would be less than [**]% if such funds were allocated to the Seller on account of Deferred Purchase Price or (B) the Trust has notified the Servicer in writing that allocations to the Seller on account of Deferred Purchase Price should cease, as specified by the Servicer, (x) to be retained in the Deposit Accounts or Collection Account until the following Business Day for allocation pursuant to Section 2.6 or 2.9, as applicable, on such following Business Day or (y) to be allocated to repay the Investment pursuant to Section 2.13 or (ii) if the Trust has not notified the Servicer in writing that allocations to the Seller on account of Deferred Purchase Price should cease, to be allocated to the Seller on account of Deferred Purchase Price after giving effect to such allocation, the quotient of (I) the ‘NRPB’, plus the amount on deposit in the Cash Reserve Account, minus ‘I’, minus ‘DP’ divided by (II) the ‘NRPB’ (as each such abbreviation is defined in the definition of “Trust’s Share”) is at least [**]%.

2.3     The proviso at the end of the definition of “Net Spread” in Section 1.1 of the Agreement is hereby amended as follows: 
; provided that the “Net Spread” calculated for the April through and including September 2020 Collection Periods shall not include (a) any addition for recoveries and Collections of principal received in respect of Defaulted Receivables as otherwise provided in clause (x)(i) above and (b) any deduction for Defaulted Receivables as otherwise provided in clause (y)(ii) above.
2.4    Clauses (o) and (cc) of Section 6.1 of the Agreement are hereby amended to read as follows:
(o) (i) as of any Settlement Date, the arithmetic average of the Net Spread for the most recent three Collection Periods (disregarding the months of April, through September of 2020) shall be [**]% or less or (ii) the Net Spread shall be less than 

2
	
		
	 
	 

(x) [**]% for any of the April, May or June 2020 Collection Periods, or (y) [**]% for any of the July, August or September 2020 Collection Periods;
(cc) (i) at any time the Trust Share exceeds [**]%, and such condition shall continue unremedied for five days after any date any Servicer Report or Portfolio Certificate is required to be delivered or (ii) for any month from and after April of 2020, the quotient of (x) the ‘NRPB’, plus the amount on deposit in the Cash Reserve Account, minus ‘I’, minus ‘DP’  divided by (y) the ‘NRPB’ (as each such abbreviation is defined in the definition of “Trust’s Share”) is less than [**]% and, in each case, such condition shall continue unremedied for five days after any date any Servicer Report or Portfolio Certificate is required to be delivered;
3.    Representations and Warranties.  The Seller, in its capacity as Seller and as Servicer, hereby represents and warrants to the Trust as follows:
(a)    Representations and Warranties.  The representations and warranties in Section 4.1 of the Agreement are true and correct as of the date hereof (unless stated to relate solely to an earlier date, in which case such representations and warranties were true and correct as of such earlier date).
(b)    Enforceability.  The execution and delivery by the Seller of this Amendment, and the performance of its obligations under this Amendment and the Agreement, as amended hereby, are within its corporate powers and have been duly authorized by all necessary corporate action on its part.  This Amendment and the Agreement, as amended hereby, are the Seller’s valid and legally binding obligations, enforceable in accordance with its terms.
(c)    Trigger Event.  No Trigger Event or any  event with the giving of notice or the lapse of time, or both, that would constitute a Trigger Event has occurred and is continuing.
4.    Effectiveness.  This Amendment shall become effective upon the receipt by the Trust of each of the counterparts of this Amendment executed by each of the parties hereto.
5.    Effect of Amendment.  Except as expressly amended and modified by this Amendment, all provisions of the Agreement shall remain in full force and effect.  After this Amendment becomes effective, all references in the Agreement (or in any other document or instrument executed in connection with the Agreement) to “the Receivables Purchase Agreement,” “this Agreement,” “hereof,” “herein” or words of similar effect, in each case referring to the Agreement, shall be deemed to be references to the Agreement as amended by this Amendment.  This Amendment shall not be deemed to expressly or impliedly waive, amend or supplement any provision of the Agreement other than as set forth herein.
6.    Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, and each counterpart shall be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Delivery of an 

3
	
		
	 
	 

executed counterpart of a signature page of this Amendment by telecopy, emailed pdf. or any other electronic means that reproduces an image of the actual executed signature page shall be effective as delivery of a manually executed counterpart of this Amendment.  The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to any  document to be signed in connection with this Amendment and the transactions contemplated hereby shall be deemed to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law; provided that nothing herein shall require the Trust to accept electronic signatures in any form or format without its prior written consent. “Electronic Signature” means an electronic sound, symbol, or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record.
7.    Governing Law.  This Amendment shall be governed by, and construed in accordance with, the laws of the Province of Ontario and the federal laws of Canada applicable therein. Each of the parties hereto hereby attorns to the non-exclusive jurisdiction of the courts of the Province of Ontario.
8.    Section Headings.  The various headings of this Amendment are inserted for convenience only and shall not affect the meaning or interpretation of this Amendment or the Agreement or any provision hereof or thereof.
9.    Reaffirmation of Performance Guarantee.  By its execution of this Amendment, the Performance Guarantor consents to the amendments to the Agreement contained herein and reaffirms its obligations under Section 8.1 of the Agreement after giving effect to this Amendment.
[SIGNATURE PAGES FOLLOW]

4
	
		
	 
	 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.
AUTOMOTIVE FINANCE CANADA INC., as Seller and initial Servicer 

 
By: /s/ Amy Wirges                                                  
Name: Amy Wirges
Title:   Sr. Vice President of Finance, Treasurer
 
 
 
KAR AUCTION SERVICES, INC., as Performance Guarantor

 
 
By: /s/ Eric M. Loughmiller                                     
Name: Eric M. Lougmiller
Title:   EVP & CFO
 
 
 

	
				
	 
	S-1
	AFC Amendment No. 6 to Fourth A&R RPA
	 

BNY TRUST COMPANY OF CANADA, in its capacity as trustee of PRECISION TRUST, by its Securitization Agent, BMO NESBITT BURNS INC.

 
 
By: /s/ John Vidinovski                                            
Name: John Vidinovski
Title:   Managing Director
 
 
 
 
By: /s/ Kevin Brown                                                
Name: Kevin Brown
Title:   DirectorEdgarFiling

Exhibit 10.1

 

 

 

July 29, 2020

 

Michael Levitz

 

 

 

Dear Michael:

 

I am pleased to confirm our offer to you
to join Anika Therapeutics, Inc. (“Anika” or the “Company”).
We are excited about the prospect of having you join our team and look forward to the addition of your professionalism and
experience to help the Company achieve its goals. This letter summarizes the initial terms of our offer for your employment
with the Company. 

 

Starting Position: Executive Vice President,
Chief Financial Officer (CFO) and Treasurer

 

Description
of Duties: You will serve as a key member of the corporate leadership team. Your initial duties will include those intrinsic
to your position, as described in the job description being provided to you with this offer letter and such other duties, reasonably
consistent with your position, as may be assigned to you from time to time. Your initial responsibilities
will include providing leadership to all aspects of Anika’s financial processes. Also, you shall be responsible for performing
any duties assigned to you by or under the authority of the Company that are appropriate for an individual of your experience.
You will be expected to devote your full business time and your best professional efforts to the performance of your duties and
responsibilities for the Company.

 

Reporting To: Cheryl Blanchard, President
and Chief Executive Officer, Anika Therapeutics, Inc.

 

Employment Date: We anticipate that you
will begin your at-will employment with Anika on August 10th.

 

Initial Rate of Pay: $17,307.70
per bi-weekly payroll (annualized $450,000.00). You will be paid in accordance with the Company’s normal payroll practices
as established or modified from time to time, and your compensation shall be subject to all applicable federal, state and local
taxes and withholdings. Currently, paychecks are issued on alternating Fridays.

 

Bonus Eligibility: You will be eligible to receive a
discretionary annual cash bonus. Your initial annual target bonus is 45% of your annualized base salary, subject to all applicable
taxes and withholdings. Your eligibility for this bonus shall be subject to determination by the Board of Directors and based on
the Company's performance and your personal performance against key objectives. Any bonus payout which may be made for 2020 will
be prorated based on your length of service in 2020. Your actual bonus payout may be adjusted depending on your and the Company’s
performance, at the sole discretion of the Company’s Board of Directors.

 

Equity Grants: Subject to the approval of the Compensation
Committee of the Board of Directors of the Company, you will be granted an equity package as of the date of the commencement of
your employment (with agreements to entered shortly thereafter). The equity package will consist of (a) restricted stock units
with a fair market value of $400,000 as of the date of grant, (b) performance stock units with a fair market value at target (i.e.,
100% achievement of the performance metrics) of $400,000 as of the date of grant, and (c) common stock options with a fair market
value (i.e., Black-Scholes value) of $800,000 as of the date of grant. The restricted stock units represent a contingent right
to receive shares of Anika’s common stock at annual intervals throughout your employment with the Company, and the performance
stock units represent a contingent right to receive shares of Anika common stock should certain performance criteria (standardized
across the Anika executive team) be met. The restricted stock units will vest ratably over three years beginning one year from
the date of hire and the performance stock units will vest when and to the extent measured by the Compensation Committee of the
Board of Directors following the audit of fiscal year 2022 in early 2023. Each will be granted under, and governed by, the Anika
Therapeutics, Inc. 2017 Omnibus Incentive Plan, and any applicable grant instruments. Continued employment with the Company is
a condition precedent to the vesting of either the restricted stock units or performance stock units. The common stock options
shall be considered “Incentive Stock Options” to the extent permissible under Section
422 of the Internal Revenue Code. The stock options represent a contingent right to purchase shares of Anika’s common stock
at an exercise price equal to the stock’s closing price on the date of the grant. The options will vest ratably over three
years beginning one year from the date of hire, and they will be granted under, and governed by, the Anika Therapeutics, Inc. 2017
Omnibus Incentive Plan, and any applicable grant instruments. Continued employment with the Company is a condition precedent to
the vesting of any incentive stock options.

 

 

	ANIKA
                           THERAPEUTICS, INC.

32 Wiggins Avenue

Bedford, MA 01730

anikatherapeutics.com

	 

                           Anika
                           customer service:

1-888-721-1600

customerservice@anikatherapeutics.com

     

     

    

 

 

Benefits: You will be eligible
to participate in the Anika employee benefit programs upon commencement of employment to the same extent as, and subject
to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure.
This program currently includes comprehensive medical and dental benefits, life and disability insurance, supplemental disability
insurance, and a Section 125 Plan. You will be eligible to participate in our 401(k) Savings and Investment Plan at the first enrollment
date (first day of each month) following your date of hire. Under the current terms, the 401(k) plan entitles you to contribute
up to the maximum limit established by the IRS. Furthermore, under the current 401(k) plan, the Company will match 140% of your
contribution up to 5% of your eligible compensation or to the limit specified by the Internal Revenue Code. There is a four-year
vesting schedule. The amount of the Company match is subject to the discretion of the Company.
Your participation in the benefit plans will be governed by and subject to the plan terms as
described in the official documents and Summary Plan Descriptions. Please note that the Company may alter, add to, modify
or delete its benefits programs at any time.

 

Vacation: You are
eligible for vacation days, which will accrue in accordance with Anika’s vacation policy, as may be modified from time to
time, in the sole discretion of the Company. Subject to the current terms of accrual and use set forth in Anika’s policies,
you will accrue four weeks of vacation during your first year of employment.

 

Termination of Employment:

 

		1)	Resignation or Termination for Cause: Notwithstanding the at-will relationship between you and
the Company, if you voluntarily resign employment or are terminated for “Cause” at any time, all compensation
and benefits payable to you under this Agreement shall terminate on the date of termination of your employment.

 

For purposes of this offer letter, “Cause”
shall mean any one or more of the following: (i) conduct constituting a material act of willful misconduct or gross negligence
in connection with the performance of your duties, including, without limitation, misappropriation of funds or property of the
Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for
personal purposes; (ii) the commission of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or
any conduct that would reasonably be expected to result in material injury to the Company or any of its subsidiaries and affiliates
if you were retained in your position; (iii) continued, willful and deliberate non-performance your duties hereunder (other than
by reason of physical or mental illness, incapacity or disability) which has continued for more than 30 days following written
notice of such non-performance from the Chief Executive Officer; (iv) a breach of any of the provisions contained in the Confidentiality
and Proprietary Rights Agreement; (v) a violation by of the Company’s employment policies which has continued following
written notice of such violation from the Board, or (vi) willful failure to cooperate with a bona fide internal investigation or
an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful
destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful inducement
of others to fail to cooperate or to produce documents or other materials in connection with such investigation. For purposes of
clauses (i), (iii) and (vi) hereof, no act, or failure to act, on the Executive’s part shall be deemed “willful”
unless done, or omitted to be done, by you without reasonable belief that your acts or failure to act, was in the best interest
of the Company and its subsidiaries and affiliates.

 

 

	ANIKA
                           THERAPEUTICS, INC.

32 Wiggins Avenue

Bedford, MA 01730

anikatherapeutics.com

	 

                           Anika
                           customer service:

1-888-721-1600

customerservice@anikatherapeutics.com

     

     

    

 

 

		2)	Termination Without Cause: Termination of your employment without Cause or in conjunction with a Change in Control shall be
regulated by the Executive Retention Agreement being provided with this Offer Letter, which shall be executed and become
effective upon your start date.

 

Confidentiality and Proprietary
Rights Agreement: You understand that as a condition of your employment, you will be required to execute Anika's Confidentiality
and Proprietary Rights Agreement, a copy of which is
enclosed. You further understand that the Anika Confidentiality and Proprietary Rights Agreement contains conditions that
will survive the termination of your employment, regardless of the reason for that termination.

 

Arbitration: Except for
any request by the Company or by you for temporary, preliminary or permanent injunctive relief from a court of competent jurisdiction
to enforce or enjoin any portion of the Confidentiality and Proprietary Rights Agreement (which right shall remain in full
force and effect following the termination of your employment with the Company), in the event of any dispute, controversy or claim
arising out of or relating to this offer letter, your employment with the Company, or the termination of your employment including
but not limited to, any claims arising out of M.G.L. ch.151B, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Family and Medical Leave Act, the Small Necessities Leave Act, the Massachusetts
Civil Rights Act (M.G.L. ch. 12), or any other federal, state or local statute, regulation or ordinance that provides protection
against employment discrimination, harassment or retaliation; any claims under the Fair Labor Standards Act or M.G.L. ch. 149 or
any other federal, state or local statute, regulation or ordinance that provides protection against wage and hour and/or wage payment
violations; any claims under the federal or state equal pay act; any tort and/or privacy claims, including those under the Massachusetts
Privacy Statute (M.G.L. ch. 214), that dispute, controversy or claim shall, to the fullest extent permitted by law, be settled
by binding arbitration before an arbitrator experienced in employment law. Said arbitration will be conducted in accordance with
the Employment Dispute Resolution Rules and Mediation Procedures of the American Arbitration Association (“AAA”) in
Boston, Massachusetts, including, but not limited to, the
rules and procedures applicable to the selection of arbitrators (or alternatively, in any other forum or in any other form agreed
upon by the parties). In the event that any person or entity other than you or Anika may be a party with regard to any such controversy
or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity's agreement. Judgment
upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This provision shall be specifically
enforceable. Arbitration as provided in this section shall be the exclusive, final and binding remedy for any such dispute and
will be used instead of any court action, which is hereby expressly waived. The Federal Arbitration Act shall govern the interpretation
and enforcement of such arbitration proceeding. The arbitrator shall apply the substantive law (and the law of remedies, if applicable)
of the Commonwealth of Massachusetts, or federal law, if Massachusetts law is preempted. You acknowledge and understand that by
agreeing to arbitrate, you are waiving any right to bring an action against the company in a court of law, either state or federal,
and the right to a trial by jury, except as otherwise expressively set forth in this agreement. 

 

 

	ANIKA
                           THERAPEUTICS, INC.

32 Wiggins Avenue

Bedford, MA 01730

anikatherapeutics.com

	 

                           Anika
                           customer service:

1-888-721-1600

customerservice@anikatherapeutics.com

     

     

    

 

 

Background Check and Drug Testing:
You understand and agree that all employees are subject to a background check, including verification
of education, and drug testing. You will be sent a link to the on-line information and release.
This offer is conditioned on the background check and drug testing results being satisfactory
to the Company. 

 

Reference Checks: You also understand and agree this
offer is contingent upon the completion of satisfactory reference checks in the sole discretion of the Company.

 

At-Will Employment: You, like everyone else at Anika,
will be an at-will employee. This means that, if you accept this offer, both you and the Company will retain the right to terminate
your employment at any time, with or without notice or cause. In accepting this offer, you give us assurance that you have not
relied on any agreement or representation, express or implied, with respect to your employment that is not set forth expressly
in this letter. The terms of your employment will be interpreted in accordance with and governed by the laws of the Commonwealth
of Massachusetts.

 

Representation Regarding Other Agreements: Finally, this
offer is conditioned on your representation that you are not subject to any confidentiality or non-competition agreement, court
order, or any similar type of restriction that would affect your ability to devote full time and attention to your work at Anika.
You further agree that you will not disclose to, or use on behalf of, the Company any proprietary information of a third party
without that party's consent.

 

Eligibility to Work. Your employment with the Company
is conditioned on your eligibility to work in the United States and on your providing to the Company proof of identification and
authorization to work in the United States, in accordance with the Immigration and Control Act of 1986. Should you choose to accept
this offer, as required by law, we must verify your employment eligibility on Form I-9 the day you begin your employment, so you
will be asked to provide documentation that establishes your identity and authorizes you to work in the United States. Furthermore,
if applicable, you must always maintain your visa status throughout your tenure with the Company, as it is Company policy to comply
with all immigration laws and regulations. Please let the Company know if you have any questions concerning your visa status.

Company Policies and Procedures. You will be required
to abide by Company policies and procedures, as in effect from time to time.

If the terms of this offer are acceptable, please indicate your
acceptance by signing both copies of this letter, the Anika Confidentiality and Proprietary Rights Agreement, and the Executive
Retention Agreement, and return one copy of each back to me. This offer is valid until July 31.

 

 

	ANIKA
                           THERAPEUTICS, INC.

32 Wiggins Avenue

Bedford, MA 01730

anikatherapeutics.com

	 

                           Anika
                           customer service:

1-888-721-1600

customerservice@anikatherapeutics.com

     

     

    

 

 

 

 

Sincerely,

 

 

/s/ Thomas Finnerty

Thomas Finnerty

Executive Vice President Human Resources

 

 

 

 

 

 

 

Agreed and accepted:

 

 

 

	/s/ Michael Levitz	 	 	July 29, 2020
	Michael Levitz	 	 	Date

 

Enclosures:

Executive Retention Agreement

Confidentiality and Proprietary Rights Agreement

Job Description

 

 

 

 

 

	ANIKA
                           THERAPEUTICS, INC.

32 Wiggins Avenue

Bedford, MA 01730

anikatherapeutics.com

	 

                           Anika
                           customer service:

1-888-721-1600

customerservice@anikatherapeutics.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]